Login to Your Account

Taiwan Liposome knee pain drug meets phase I/II target

By Shannon Ellis
Staff Writer

Wednesday, January 11, 2017

SHANGHAI – Taiwan Liposome Co. (TLC) is hoping to give patients with osteoarthritis of the knee a better option for pain management with TLC599, a steroid API wrapped in a sustained release liposome delivery package. The company released positive top line results from a phase I/II data for a trial in Taiwan and Australia, and kicked off a phase II trial in both places with plans underway for China and the U.S.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription